NICE

News

NICE recommends Alexion's long-acting Ultomiris for PNH

NICE has recommended Alexion’s long-acting Ultomiris (ravulizumab) for the rare disease paroxysmal nocturnal haemoglobinuria (PNH) in final draft guidance.

News

NICE backs Sobi's Kineret for rare inflammatory disease

The UK's cost-effectiveness agency NICE has recommended that Sobi's Kineret can be used to treat NHS patients with Still's disease, a rare form of arthritis affecting children and adults.

Views & Analysis

NICE methods and process review aims to create fertile groun...

The way NICE reviews new medicines is about to go through its biggest change in years – but what do the proposals mean for the future of drug development in the UK?

News

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

NICE backs ovarian cancer and multiple myeloma combination d...

NICE has recommended funding for two cancer drug combinations for ovarian cancer and multiple myeloma.

News

NICE axes funding for MSD's Keytruda in bladder cancer despi...

NICE has axed funding for MSD’s Keytruda for second-line advanced bladder cancer in final guidance, despite an appeal from the company.

News

NICE backs AZ’s Calquence for new use in leukaemia

AstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS England patients with chronic lymphocytic leukaemia (CLL) who can’t be treated

NICE recommends Alexion's long-acting Ultomiris for PNH

NICE backs Sobi's Kineret for rare inflammatory disease

NICE methods and process review aims to create fertile groun...

NICE backs ovarian cancer and multiple myeloma combination d...

NICE axes funding for MSD's Keytruda in bladder cancer despi...

NICE backs AZ’s Calquence for new use in leukaemia

EU invests €30m to fight antimicrobial resistance

Using AI-driven synthetic personas to take your insights fur...

NICE

Editor's Picks